Univest
Univest
  • Markets

SYMBIOTEC PHARMALAB (SYMBIOTEC) Share Price Rises 5.25% Today

  • September 7, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
SYMBIOTEC Share Price
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) share price rose to Rs 1,159.25 today, up 5.25% from the previous close. Market cap was Rs 6,990.1 crore.

SYMBIOTEC Share Price rose in early trade on 13 October 2026, with SYMBIOTEC PHARMALAB LTD last traded at Rs 1,159.25, up 5.25% from the previous close of Rs 1,101.4. The company’s market capitalisation stands at Rs 6,990.1 Cr. According to latest Univest figures, the price event is confirmed, but no company-specific catalyst is established. That makes the move relevant from a price action and valuation angle rather than a news-led one.

For readers tracking SYMBIOTEC Share Price Today, the stock opened at Rs 1,108.6, touched a high of Rs 1,161 and a low of Rs 1,108.6 in the current move. The latest Univest figures show a gain of Rs 57.85 over the previous close, placing the stock near the day’s high. In SYMBIOTEC Stock News terms, the important point is the verified price rise itself. On Univest, the focus now shifts to whether the valuation and sector backdrop justify the current SYMBIOTEC Share Price level.

Table of Contents

Toggle
  • SYMBIOTEC Share Price Today: Price Action Analysis
  • SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching SYMBIOTEC PHARMALAB LTD
  • About SYMBIOTEC PHARMALAB LTD
  • Frequently Asked Questions
    • What is SYMBIOTEC Share Price today?
    • Why is SYMBIOTEC Share Price rising today?
    • What is SYMBIOTEC Share Price market cap?
    • Is SYMBIOTEC Share Price expensive versus peers?
    • What do EPS and book value show for SYMBIOTEC Share Price?
    • Does SYMBIOTEC Share Price offer a dividend yield?
    • What should investors monitor in SYMBIOTEC Share Price?
  • Track SYMBIOTEC Share Price on Univest

SYMBIOTEC Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 1,159.25
Previous Close Rs 1,101.4
Today's Move Rs 57.85 (+5.25%)
Open Rs 1,108.6
High Rs 1,161
Low Rs 1,108.6
Market Capitalisation Rs 6,990.1 crore
Market Cap Category Mid Cap

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) rose to Rs 1,159.25 from the previous close of Rs 1,101.4, a move of Rs 57.85 or 5.25%. The stock opened at Rs 1,108.6, reached a high of Rs 1,161, recorded a low of Rs 1,108.6.

SYMBIOTEC Share Price Today shows a clear intraday rise, with the stock moving from Rs 1,108.6 at the open to Rs 1,159.25 last traded, after touching Rs 1,161 during the ongoing trade. The current move of Rs 57.85, or 5.25%, reflects the day’s strongest verified price change so far.

The session range matters because it shows how the SYMBIOTEC Share Price has traded between Rs 1,108.6 and Rs 1161, with the last traded price staying close to the upper end of that band. For SYMBIOTEC Share Price Live tracking, the previous close of Rs 1,101.4 is the anchor point for today’s move. The market cap at Rs 6,990.1 Cr gives the price action a defined scale in the Healthcare space. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. That leaves the day’s trading pattern as the key observable fact for SYMBIOTEC Share Price monitoring.

This is why the current SYMBIOTEC Share Price Update deserves attention alongside the broader SYMBIOTEC Stock Performance view, especially before moving into SYMBIOTEC Fundamental Analysis.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis

Metric Value
Market Capitalisation Rs 6,990.1 crore
P/E Ratio 64.39x
P/B Ratio 4.72x
ROE 11.22%
ROCE 12.41%
EPS Rs 17.1
Book Value Per Share Rs 233.38
Dividend Yield 0%

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 64.39x, P/B 4.72x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.

SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 6,990.1 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 64.39x, P/B at 4.72x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.63x, median ROE of 11.61%, median ROCE of 13.46%. Taken together, they outline the fundamentals rather than a view on the stock.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 64.39x
Benchmark Median P/E 31.63x
Benchmark Average P/E 47.13x
Benchmark P/E Range 3.21x to 676.52x
Company P/B Ratio 4.72x
Benchmark Median P/B 2.86x
Company ROE 11.22%
Benchmark Median ROE 11.61%
Company ROCE 12.41%
Benchmark Median ROCE 13.46%
Company Market Capitalisation Rs 6,990.1 crore
Benchmark Median Market Cap Rs 814.52 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 64.39x, which is above the benchmark median of 31.63x, a difference of +103.57%. On its own, the P/E gap is a valuation reference point, not a trading call.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.61%, a difference of -3.36%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.46%, a difference of -7.8%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries Ltd. SUNPHARMA 4,21,539.16 34.89 4.88 14.85 19.11
Divi's Laboratories Ltd. DIVISLAB 2,47,576 85.12 14.1 16.19 21.51
Torrent Pharmaceuticals Ltd. TORNTPHARM 1,77,251.42 81.6 19.83 26.76 19.27
Zydus Lifesciences Ltd. ZYDUSLIFE 1,11,231.65 25.18 4.21 19.69 21.39
Laurus Labs Ltd. LAURUSLABS 1,09,796.85 102.34 19.84 18.31 18.2

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 64.39x compared with the displayed peer median of 81.6x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 11.22% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 6,990.1 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching SYMBIOTEC PHARMALAB LTD

  • SYMBIOTEC Share Price is rising today by 5.25%, with the last traded price at Rs 1,159.25.
  • The day’s range, from Rs 1,108.6 to Rs 1161, keeps SYMBIOTEC Share Price Today near the higher end of intraday trade.
  • SYMBIOTEC Fundamental Analysis shows a P/E of 64.39 and P/B of 4.72, both above the industry median.
  • ROE of 11.22% and ROCE of 12.41% give context to the current SYMBIOTEC Share Price valuation.
  • SYMBIOTEC Stock News remains event-led today because the price rise is confirmed, while no company-specific catalyst is established.

About SYMBIOTEC PHARMALAB LTD

SYMBIOTEC PHARMALAB LTD operates in Healthcare and belongs to the Pharmaceuticals & Drugs industry. The company’s current SYMBIOTEC Share Price is being tracked by market participants because its valuation and return metrics offer a defined comparison point within the pharma pack. Based on the available business context, it is positioned as a listed pharmaceutical company with a market capitalisation of Rs 6,990.1 Cr.

For readers reviewing SYMBIOTEC Share Price Today alongside sector context, the key point is that the company sits in a large and diverse industry benchmark of 199 peers. That makes SYMBIOTEC Stock Performance more meaningful when viewed with P/E, P/B, ROE, ROCE, EPS, book value and dividend yield rather than price alone. Univest users often track this kind of stock through a combination of SYMBIOTEC Share Price movement and core fundamentals.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What is SYMBIOTEC Share Price today?

Ans. SYMBIOTEC Share Price is Rs 1,159.25, up 5.25% from the previous close of Rs 1,101.4. The stock traded between Rs 1,108.6 and Rs 1,161 in the current move.

Why is SYMBIOTEC Share Price rising today?

Ans. According to latest Univest figures, the price event is confirmed, but no company-specific catalyst is established. The move is a verified intraday price rise, not a news-linked explanation.

What is SYMBIOTEC Share Price market cap?

Ans. SYMBIOTEC Share Price is associated with a market capitalisation of Rs 6,990.1 Cr. In the same industry benchmark, this is below the average market cap and above the median.

Is SYMBIOTEC Share Price expensive versus peers?

Ans. SYMBIOTEC Share Price trades at a higher P/E than several peers such as Zydus Lifesciences, Cipla and Dr. Reddy’s, but below Divi’s Laboratories, Torrent Pharmaceuticals and Laurus Labs. The P/B is also above some peers.

What do EPS and book value show for SYMBIOTEC Share Price?

Ans. EPS is 17.1 and book value is Rs 233.38 per share. These numbers help place SYMBIOTEC Share Price against earnings support and accounting net worth per share in valuation work.

Does SYMBIOTEC Share Price offer a dividend yield?

Ans. Dividend yield is 0%, so SYMBIOTEC Share Price does not include a dividend payout layer in the current valuation view. The focus stays on price action, earnings multiples and return ratios.

What should investors monitor in SYMBIOTEC Share Price?

Ans. Investors tracking SYMBIOTEC Share Price should monitor whether the current price remains near the day’s upper range, and whether future financial updates support the existing P/E, P/B, ROE and ROCE profile.

Track SYMBIOTEC Share Price on Univest

Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

If you want to follow SYMBIOTEC Share Price beyond today’s move, Univest helps you track live price, valuation ratios, 52-week levels and market insights in one place. You can use SYMBIOTEC Share Price Today tracking to monitor how the stock behaves against its sector benchmark and peer set. Univest keeps the SYMBIOTEC Share Price view tied to fundamentals, not just one trading session.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply